We are live on
!
Find out more
WCM
Wildcat Capital Management Portfolio holdings
AUM
$229M
1-Year Est. Return
132.65%
This Fund
S&P 500
This Quarter
Est. Return
+15.33%
1 Year Est. Return
+132.65%
3 Year Est. Return
+125.67%
5 Year Est. Return
+54.1%
10 Year Est. Return
+1,929.91%
AUM
$121M
AUM Growth
+$27.2M
(+29%)
Cap. Flow
+$11M
Cap. Flow
% of AUM
9.06%
Top 10 Holdings %
Top 10 Hldgs %
95.54%
Holding
15
New
4
Increased
3
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Editas Medicine
EDIT
|
+$6.62M |
| 2 |
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
|
+$5.17M |
| 3 |
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
|
+$3.03M |
| 4 |
Dave & Buster's
PLAY
|
+$2.77M |
| 5 |
UroGen Pharma
URGN
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRNE
Sorrento Therapeutics, Inc.
SRNE
|
+$9.41M |
| 2 |
ImmunityBio
IBRX
|
+$1.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 45.78% |
| 2 | Healthcare | 18.89% |
| 3 | Financials | 10.5% |
| 4 | Energy | 10.44% |
| 5 | Communication Services | 4.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CoStar Group
CSGP
$11.7B
| $55.5M | 45.78% |
1,530,070
| – | – |
|
2
LPL Financial
LPLA
$28.3B
| $12.7M | 10.5% |
208,401
| – | – |
|
|
SBR
3
Sabine Royalty Trust
SBR
$1.06B
| $12.7M | 10.44% |
289,790
+50,473
| +21% | +$2.26M |
|
|
4
UroGen Pharma
URGN
$1.86B
| $9.03M | 7.45% |
181,702
+54,389
| +43% | +$2.72M |
|
|
5
Editas Medicine
EDIT
$396M
| $6.16M | 5.08% |
+185,668
| New | +$6.62M |
|
|
SNNA
6
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
| $5.55M | 4.58% |
+295,613
| New | +$5.17M |
|
|
7
Dave & Buster's
PLAY
$377M
| $5.01M | 4.13% |
120,000
+60,000
| +100% | +$2.77M |
|
|
VXX
8
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
| $3.79M | 3.12% |
+80,000
| New | +$3.03M |
|
|
PLYA
9
DELISTED
Playa Hotels & Resorts
PLYA
| $3.07M | 2.53% |
300,000
| – | – |
|
10
AppFolio
APPF
$6.38B
| $2.34M | 1.93% |
57,372
| – | – |
|
|
11
ImmunityBio
IBRX
$7.51B
| $2.17M | 1.79% |
556,453
-252,521
| -31% | -$1.11M |
|
|
SRNE
12
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $2.14M | 1.77% |
415,765
-1,322,467
| -76% | -$9.41M |
|
|
NH
13
DELISTED
NantHealth, Inc
NH
| $611K | 0.5% |
13,358
| – | – |
|
|
COUP
14
DELISTED
Coupa Software Incorporated
COUP
| $488K | 0.4% |
+10,704
| New | +$440K |
|
15
CALL
United States Natural Gas Fund
UNG
$456M
| – | – |
-4,059
| Closed | -$1.51M |
|
Similar funds
AFO
CNHF
GCM
CM
CSIA
AF
NIA
HFA
Wildcat Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Wildcat Capital Management held 15 positions worth $121M, up 29% from $94M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Wildcat Capital Management deployed $11M of net new capital in Q1 2018, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Editas Medicine: 185,668 shares worth $6.16M.
By sector, the portfolio is most concentrated in Real Estate at 46% of assets, down from 48% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Sorrento Therapeutics, Inc., an estimated $9.41M trimmed.
- Wildcat Capital Management's largest Q1 2018 buy was Editas Medicine: 185,668 shares worth $6.16M.
- Wildcat Capital Management added most to Dave & Buster's in Q1 2018, an estimated $2.77M increase.
- Wildcat Capital Management's biggest Q1 2018 reduction was Sorrento Therapeutics, Inc., cutting an estimated $9.41M.
- Wildcat Capital Management's ten largest holdings make up 96% of its $121M portfolio in Q1 2018.
- Wildcat Capital Management opened 4 new positions and closed 1 in Q1 2018.
- Wildcat Capital Management's portfolio value rose 29% quarter-over-quarter to $121M.
Based on Wildcat Capital Management's 13F filing for Q1 2018, filed 15 May 2018.